期刊文献+

聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化疗效探讨 预览

To Investigate the Efficacy of Pegylated Interferon α-2a Combination With Ribavirin in Treatment of Hepatitis C and Cirrhosis Patients
在线阅读 免费下载
收藏 分享 导出
摘要 目的探讨聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化的临床疗效及安全性。方法将62例失代偿期丙肝后肝硬化患者随机分为两组,对照组给予常规治疗,研究组采用聚乙二醇干扰素α-2a联合利巴韦林治疗方案,评价两组临床疗效及不良反应情况。结果两组治疗前肝功能指标TBi L、ALT、AST等差异无统计学意义(P〉0.05),但治疗后上述指标均较治疗前下降(P〈0.05),且研究组下降幅度大于对照组(P〈0.05)。结论聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化疗效确切,抗纤维化效果好。 Objective To explore the clinical efficacy and safety of pegylated interferon α-2a combination with Ribavirin in treatment of hepatitis C and cirrhosis patients. Methods 62 cases of patients with hepatitis C and cirrhosis were randomly divided into two groups. The control group received conventional treatment, research group withpeginterferon α-2a and ribavirin treatment, to evaluate the clinical efficacy and adverse reactions of the two groups. Results The TBi L, ALT, AST of liver function was not statistically significant in two group before treatment(P〉0.05), but after treatment, this indicators were significantly decreased than treatment before(P〈0.05), and the decline in the study group was significantly higher than the control group(P〈0.05). Conclusion Pegylated interferon α-2a combination with Ribavirin treatment of hepatitis C and cirrhosis patients has exact effect and antifibrosis.
作者 陈瑞红 CHEN Ruihong(Infectious department, Sanmenxia city centre hospital affiliated to He’nan university of science and technology; Sanmenxia 472000, China)
出处 《中国继续医学教育》 2015年第32期146-147,共2页 China Continuing Medical Education
关键词 聚乙二醇干扰素Α-2A 利巴韦林 代偿期丙肝后肝硬化 疗效 Pegylated interferon α-2a Ribavirin Hepatitis C and cirrhosis Efficacy
  • 相关文献

二级参考文献19

共引文献4

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈